Daily Ards Research Analysis
Analyzed 19 papers and selected 3 impactful papers.
Summary
Analyzed 19 papers and selected 3 impactful articles.
Selected Articles
1. Efficacy of β-agonists in prevention and treatment of acute lung injury: A meta-analysis of randomized controlled trials.
Across six RCTs (n=1213), beta-agonists worsened key outcomes in ALI/ARDS: fewer ventilator- and ICU-free days, higher 90-day mortality (RR 1.39), and increased arrhythmias (RR 1.89). No benefit was seen for organ failure-free days. These data argue against beta-agonist use in ALI/ARDS.
Impact: Provides high-level synthesis showing harm from beta-agonists in ALI/ARDS, directly informing practice by consolidating safety signals across RCTs.
Clinical Implications: Avoid beta-agonists for ALI/ARDS treatment or prevention due to increased long-term mortality and arrhythmia risk and lack of clinical benefit.
Key Findings
- Reduced ventilator-free days (mean difference −1.98; P=0.002; I2=68%).
- Reduced ICU-free days (mean difference −6.57; P=0.001).
- Increased 90-day mortality (RR 1.39; 95% CI 1.03–1.89; P=0.03).
- Trend toward higher 28-day mortality (RR 1.23; P=0.10).
- Increased cardiac arrhythmias (RR 1.89; P=0.0008).
- No significant effect on organ failure-free days (mean difference −0.99; P=0.31).
Methodological Strengths
- Inclusion limited to randomized controlled trials.
- Comprehensive search across five databases with standardized effect metrics.
- Risk of bias assessed with Cochrane tool; heterogeneity quantified (Q, I2).
- Sensitivity analyses performed to confirm robustness.
Limitations
- Clinical heterogeneity across trials (β-agonist type, dosing, route, timing).
- Moderate statistical heterogeneity for some outcomes (e.g., ventilator-free days, I2=68%).
- Limited number of trials restricts subgroup analyses.
Future Directions: Clarify mechanisms underlying harm from beta-agonists in ALI/ARDS; identify if any narrow subgroups could benefit; prioritize alternative pharmacologic targets with stronger biological rationale.
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) carry high mortality with limited drug therapies. β-agonists are potential candidates due to bronchodilatory and anti-inflammatory effects. This meta-analysis evaluated their efficacy and safety in ALI/ARDS. Randomized controlled trials (RCTs) of β-agonists in ALI/ARDS were identified through PubMed, Cochrane Library, Embase, Web of Science, and Scopus. Relative risks were used for dichotomous outcomes and mean differences for continuous outcomes. The Cochrane tool was used to evaluate bias, and Cochran's Q and the I2 statistics were used to evaluate heterogeneity. Six RCTs involving 1213 participants met the inclusion criteria. Beta-agonists significantly reduced ventilator-free days (mean difference - 1.98, 95% confidence interval [CI]: -3.21 to - 0.75, P = 0.002, I2 = 68%) and intensive care unit (ICU)-free days (-6.57, P = 0.001). They were associated with nonsignificant trend toward higher 28-day mortality (risk ratio: 1.23, P = 0.10) and a significant increase in 90-day mortality (risk ratio: 1.39, 95% CI: 1.03-1.89, P = 0.03). Sensitivity analysis confirmed robust results, showing increased risk of cardiac arrhythmias (risk ratio: 1.89, P = 0.0008) but no significant effect on organ failure-free days (-0.99, P = 0.31). In ARDS/ALI, β-agonists reduce ventilator-and ICU-free days but increase 90-day mortality and arrhythmia risk, with no impact on organ failure-free days. β-agonists are linked to long-term risks, such as increased mortality and arrhythmias, but they provide little clinical benefit in terms of reducing ventilator or intensive care unit time. They have no effect on the incidence of ARDS/ALI or outcomes of organ failure.
2. Trends and mortality due to acute respiratory distress syndrome in the United States (1999-2023): A 25-year nationwide study.
Using 364,924 ARDS-related deaths from CDC WONDER, age-adjusted mortality fell from 1999–2018, surged during 2018–2021, and declined again by 2023. Mortality was higher among men, older adults, racial/ethnic minorities, rural residents, and in the South/Midwest, underscoring persistent disparities amplified by the COVID-19 pandemic.
Impact: Provides a comprehensive, national, 25-year view of ARDS mortality with rigorous trend analysis, revealing pandemic-era surges and structural disparities that inform policy and resource allocation.
Clinical Implications: Prioritize equitable critical care resources, targeted outreach to high-risk demographics and regions, and pandemic preparedness to mitigate future ARDS deaths.
Key Findings
- AAMRs declined 1999–2018 (APC −2.63; 95% CI −4.74 to −1.04), surged 2018–2021 (APC 85.78), and decreased 2021–2023 (APC −59.59).
- Overall AAPC was −1.90 (95% CI −3.80 to 0.19) across 1999–2023.
- Higher mortality in males and those aged ≥75 years.
- Disproportionately elevated mortality among non-Hispanic Black, Hispanic/Latino, and American Indian/Alaska Native populations.
- Rural areas and South/Midwest experienced greater pandemic-era increases; CA, TX, FL, NY had highest cumulative counts.
Methodological Strengths
- Nationwide population-based dataset (CDC WONDER) spanning 25 years.
- Use of Joinpoint regression to quantify temporal changes (APC/AAPC) with CIs.
- Stratification by sex, age, race/ethnicity, geography, and urbanization.
Limitations
- Reliance on death certificate coding (ICD-10 J80) may introduce misclassification.
- Ecologic design lacks patient-level clinical covariates and causal inference.
- Cannot capture ARDS incidence or in-hospital management details.
Future Directions: Link vital statistics to clinical registries to refine risk adjustment; evaluate access-to-care and ICU capacity as mediators of disparities; develop early-warning systems for ARDS surges.
Acute respiratory distress syndrome (ARDS) remains a significant cause of morbidity and mortality in the United States. Although advances in critical care have improved outcomes, the Coronavirus Disease of 2019 (COVID-19) pandemic substantially altered ARDS epidemiology, necessitating updated analyses of national mortality trends. To examine 25-year trends (1999-2023) in ARDS-related mortality across demographic, geographic, and urbanization categories, and to evaluate the impact of the COVID-19 pandemic on these patterns. We conducted a population-based descriptive study using CDC WONDER multiple cause-of-death data. ARDS-related deaths were identified by ICD-10 code J80. Crude and age-adjusted mortality rates (AAMRs) per 100,000 population were calculated. Temporal changes were analyzed using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC) with 95% confidence intervals. Mortality rates were stratified by sex, age, race/ethnicity, census region, state, and urban-rural classification. Between 1999 and 2023, 364,924 ARDS-related deaths were recorded. National AAMRs declined steadily from 1999 to 2018 (APC -2.63; 95% confidence interval (CI): -4.74--1.04), surged sharply during 2018 to 2021 (APC 85.78; 95% CI: 53.65-109.16), and decreased between 2021 and 2023 (APC -59.59; 95% CI: -68.58--47.89), resulting in an overall AAPC of -1.90 (95% CI: -3.80-0.19). Males consistently exhibited higher mortality rates than females. Individuals aged ≥ 75 years had the highest AAMRs. Non-Hispanic Black, Hispanic/Latino, and American Indian/Alaska Native populations experienced disproportionately elevated mortality. Rural areas and the South and Midwest regions showed greater increases during the pandemic. California, Texas, Florida, and New York reported the highest cumulative death counts. ARDS mortality in the United States declined for nearly 2 decades but rose sharply during the COVID-19 pandemic, highlighting persistent disparities by age, sex, race, geography, and urbanization. Targeted interventions and equitable critical care access are essential to reduce future ARDS-related deaths. Detailed Visual Abstract is illustrated in the Central Illustration.
3. A nomogram for predicting ARDS progression and need for invasive ventilation in COVID-19 patients using plasma hyaluronic acid and clinical scores.
In 502 hospitalized COVID-19 patients, plasma hyaluronic acid measured within 24 hours showed strong discrimination for ARDS (AUC 0.904), severe ARDS (AUC 0.953), and intubation risk (AUC 0.890). Combining HA with clinical variables and severity scores further improved model performance, supporting HA as a complementary early risk stratification biomarker.
Impact: Introduces a readily measurable biomarker with high AUCs for ARDS diagnosis, severity, and intubation risk in COVID-19, and proposes a nomogram integrating HA with clinical scores.
Clinical Implications: Consider early HA testing on admission to support triage and escalation decisions in COVID-19, while recognizing the need for external validation and standardization of cutoffs before routine adoption.
Key Findings
- HA discriminated ARDS with AUC 0.904 (cutoff 103 μg/L; sensitivity 81.6%, specificity 87.5%).
- HA discriminated severe ARDS with AUC 0.953, comparable to APACHE II and SOFA.
- Intubation risk predicted with AUC 0.890 (cutoff 140.1 μg/L; sensitivity 76.6%, specificity 90.8%, NPV 95.5%).
- Adding HA to clinical variables increased AUC for severe ARDS from 0.960 to 0.973 (ΔAUC 0.013).
- HA independently associated with ARDS diagnosis (OR 1.04; P=0.007), severe ARDS (OR 1.00; P<0.001), and intubation risk (OR 1.00; P=0.011).
Methodological Strengths
- Moderate sample size (n=502) with early biomarker measurement within 24 hours.
- Use of ROC analysis, multivariable logistic regression, and nomogram construction.
- Comparison with established severity scores (APACHE II, SOFA) and combined modeling.
Limitations
- Single-center retrospective design limits generalizability and causal inference.
- Marginal AUC gain when adding HA to strong clinical models (ΔAUC 0.013).
- No external validation; assay-specific cutoffs may limit portability.
Future Directions: Prospective, multicenter external validation with standardized HA assays; assess added clinical utility via decision-curve analysis and impact on patient outcomes.
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a major complication in hospitalized patients with coronavirus disease 2019 (COVID-19). Early identification of patients at increased risk of ARDS progression and invasive ventilation remains clinically important. This study aimed to investigate whether plasma hyaluronic acid (HA), alone or in combination with established clinical severity scores, could help identify ARDS, stratify severe disease, and assess the risk of endotracheal intubation in patients with COVID-19. METHODS: This retrospective single-center cohort study included 502 adult patients with COVID-19 admitted between September 2022 and February 2023. Plasma HA levels were measured within 24 hours after admission. Demographic characteristics, comorbidities, laboratory findings, clinical severity scores, and outcome data were collected. Receiver operating characteristic analysis, multivariable logistic regression, and nomogram construction were used to evaluate the association of HA with ARDS diagnosis, severe ARDS stratification, and intubation risk. RESULTS: This retrospective cohort analysis of 502 COVID-19 patients (361 in the non-ARDS group and 141 in the ARDS group) identified plasma hyaluronic acid (HA) as a potential biomarker for early ARDS diagnosis, severity stratification, and intubation risk assessment. HA levels were positively correlated with disease severity, with concentrations significantly increasing alongside ARDS severity, and showed good discrimination for ARDS (AUC = 0.904; sensitivity 81.6%, specificity 87.5% at a cut-off of 103 μg/L). HA also demonstrated excellent discrimination for severe ARDS, with an AUC of 0.953, comparable to that of the APACHE II and SOFA scores. It also showed good discrimination for endotracheal intubation risk in the overall cohort. The AUC for predicting intubation requirement reached 0.890 (sensitivity 76.6%, specificity 90.8%, NPV = 95.5% at a cut-off value of 140.1 μg/L). Integrating HA with clinical scores further improved model performance; incorporating age, lymphocyte count, CRP, CK, APACHE II, and SOFA into the baseline model increased the AUC for predicting severe ARDS from 0.960 to 0.973 (ΔAUC = 0.013). Furthermore, multivariable regression analysis showed that HA was independently associated with ARDS diagnosis (OR = 1.04, P = 0.007), severe ARDS (OR = 1.00, P < 0.001), and intubation risk (OR = 1.00, P = 0.011). CONCLUSION: Plasma HA was positively associated with ARDS severity and intubation risk in patients with COVID-19. HA may serve as a complementary biomarker for early risk stratification, particularly when used in combination with established clinical severity scores.